Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the liquid biopsy for cancer diagnostics market size evolved in recent years?

The market size of liquid biopsy for cancer detection has seen swift growth in the past few years. It is estimated to expand from $9.23 billion in 2024 to $10.78 billion in 2025, marking a compound annual growth rate (CAGR) of 16.8%. This significant growth in the historical period is due to the progress in genomic research, increased consciousness about the advantages of liquid biopsy, surging prevalence of cancer, escalating demand for non-invasive cancer diagnosis, and the growth of precision medicine initiatives.

What are the predictions for the liquid biopsy for cancer diagnostics market size in the coming years?

Anticipated to undergo swift expansion in the coming years, the liquid biopsy for cancer diagnostics market is predicted to reach a value of $19.32 billion in 2029, with a compound annual growth rate (CAGR) of 15.7%. Factors contributing to this growth forecast include the implementation of liquid biopsy in regular cancer diagnostics, the use of liquid biopsy for early cancer detection, growth of cancer screening programs, a heightened emphasis on personalized medicine in cancer care, and increased funding for research on liquid biopsy. Key trends that will shape the industry in the forecast period encompass the rise of multi-omics liquid biopsy methods, the incorporation of artificial intelligence in liquid biopsy examination, widening the use of liquid biopsy beyond cancer, the creation of blood-based biomarkers for cancer, and tailoring liquid biopsy tests for distinct types of cancer.

Get your liquid biopsy for cancer diagnostics market report here!

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

What key factors are fueling the growth of the liquid biopsy for cancer diagnostics market?

The escalating rate of cancer is anticipated to boost the expansion of the liquid biopsy for cancer diagnostics market. Cancer encompasses a broad range of diseases that can emerge anywhere in the body when abnormal cells multiply out of control, exceed their normal limits and either metastasize to other organs or infiltrate nearby body structures. Cancer amplifies the requirement for diagnostic routines such as early detection of cancer or tumor recurrence, risk analysis for each patient and monitoring of therapy, enabling liquid biopsy to reflect the complete disease landscape as tumor cells or tumor cell by-products are discharged from all metastatic or primary tumor locations, offering comprehensive and current data on tumor cell evolution, therapeutic objectives, and therapy resistance mechanisms. For example, the National Cancer Institute, a U.S. government agency, stated in May 2024 that about 18.1 million people in the United States survived cancer. This number is forecasted to shoot up to 22.5 million by the year 2032. By 2040, the recorded new cases of cancer per year is predicted to hit 29.9 million, where cancer relevant fatalities are speculated to surge to 15.3 million. Hence, the surging prevalence of cancer is fueling the progression of the liquid biopsy for cancer diagnostics market.

How is the global liquid biopsy for cancer diagnostics market divided into key segments?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Who are the key firms paving the way for growth in the liquid biopsy for cancer diagnostics market?

Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Which trends are expected to transform the liquid biopsy for cancer diagnostics market?

In the liquid biopsy for cancer diagnostics market, product innovation has rapidly become a key trend. To solidify their market presence, major firms in the field are focusing on the development of inventive products. For example, BostonGene, a biomedical software company from the US, introduced new liquid biopsy solutions in June 2023 to detect important gene changes clinically. The expansion of the test portfolio will speed up the development of new tests, analytical tools, and processes to give patients access to precision medicine. The approach amalgamates several artificial intelligence-powered techniques for molecular and immunological profiling to examine tumors, microenvironments, and host immunity. Furthermore, it aids in the delivery of immunotherapy treatment, supplies information on immune-system related diseases in patients, and keeps track of disease progression and response to therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205

What regions are contributing significantly to the growth of the liquid biopsy for cancer diagnostics market?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Bioabsorbable Stents Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Cardiovascular Medical Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

Blood Collection Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: